Castaneda Serguei A, Romak Lindsay B
Department of Radiation Oncology, Helen F. Graham Cancer Center & Research Institute, Christiana Care Health System, 4701 Ogletown-Stanton RR, S-1110, Newark, DE 19713, USA; Department of Radiation Oncology, Drexel University College of Medicine, 245 North 15th Street, MS #200, Philadelphia, PA 19102, USA.
Department of Radiation Oncology, Helen F. Graham Cancer Center & Research Institute, Christiana Care Health System, 4701 Ogletown-Stanton RR, S-1110, Newark, DE 19713, USA.
Surg Oncol Clin N Am. 2017 Jul;26(3):467-475. doi: 10.1016/j.soc.2017.01.004. Epub 2017 May 11.
The treatment of anal cancer has evolved remarkably in the past 30 years. Definitive chemoradiotherapy is the standard of care, allowing organ preservation and maintenance of continence for most patients. This article reviews recent advances in radiotherapy planning and delivery that have resulted in improvements in treatment-related toxicity. Most notably, the advent and wide adoption of intensity-modulated radiotherapy provides a superior toxicity profile compared with older techniques, while maintaining similar oncologic outcomes. Current areas of active research include optimizing and individualizing treatment intensity and possible integration of biologic agents and immunotherapies in the treatment of anal cancer.
在过去30年中,肛门癌的治疗有了显著进展。确定性放化疗是标准治疗方法,能使大多数患者保留器官并维持控便能力。本文综述了放疗计划和实施方面的最新进展,这些进展改善了与治疗相关的毒性。最值得注意的是,调强放疗的出现和广泛应用与旧技术相比,在保持相似肿瘤学疗效的同时,毒性反应更小。当前的活跃研究领域包括优化和个体化治疗强度,以及在肛门癌治疗中可能整合生物制剂和免疫疗法。